arrow
T

Torben Lüders

University of Oslo
H指数:20
被引数:1,768

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor mutational burden (TMB), BRAF status, and C-reactive protein (CRP) predict response to first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC)

肿瘤突变负荷(TMB)、BRAF状态和C反应蛋白(CRP)可预测微卫星稳定(MSS)结直肠癌(CRC)患者对一线奥沙利铂为基础化疗联合纳武利尤单抗的应答。

2024-09-010
PRE
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer

NEOLETRIB试验: 在ER阳性,HER2-negative乳腺癌中使用来曲唑和Ribociclib进行新辅助治疗

2024-07-290
OAAI
Cancer and immune cells evolutionary trajectories under treatment with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib
2024-05-020
PRE
Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)
2024-03-220
PRE
Single cell characterization of longitudinal biopsies from breast cancer patients treated neoadjuvantly with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib in concert
2023-03-010
OA
Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study
2022-02-150
PRE
ZBTB11 dysfunction: spectrum of brain abnormalities, biochemical signature and cellular consequences
BRAIN
IF11.7
2022-02-016
OAAI